When does GH-axis intervention make sense for age-related decline, what labs do I need, and which peptide fits which goal?

The biology of age-related GH decline

Evidence tier: 2 — well-characterized endocrinology.

Growth hormone secretion peaks during adolescence, plateaus through the 20s, and begins a gradual but predictable decline starting in the late 20s to early 30s. By age 60, average GH secretion is roughly 30-50% of young-adult values. The decline has several components:

• Reduced overnight GH pulse amplitude during slow-wave sleep — the largest single pool of daily GH release
• Increased somatostatin tone suppressing pituitary GH output
• Reduced hypothalamic GHRH release
• Preserved (mostly) pituitary somatotroph responsiveness to exogenous GHRH — this is the basis for GHRH-analog therapy working in older adults
• Body composition changes (increased visceral fat, reduced lean mass) that further suppress GH output

The downstream effect is reduced IGF-1 production by the liver and target tissues. IGF-1 declines roughly in parallel with GH, though the exact relationship varies with nutritional status, body composition, and gonadal hormone status.

This decline is normal, age-expected, and not a disease in itself. It overlaps with the changes that come with aging — sleep fragmentation, body composition shift, recovery slowing, cognitive efficiency drop — but the causal relationships are bidirectional and incompletely characterized.

When to consider GH-axis intervention

Evidence tier: 3 — clinical judgment + evidence framework.

GH-axis intervention is reasonable to consider when:

• Age >40 with documented IGF-1 below mid-normal-for-age, AND
• Symptoms plausibly attributable to GH-axis decline — poor sleep quality despite adequate sleep hygiene, post-exercise recovery slowing, body composition shift despite stable diet/training, reduced morning energy
• Conventional drivers addressed: sleep apnea screened, gonadal hormone status assessed (testosterone in men, post-menopause status in women), thyroid status confirmed, vitamin D sufficient, basic lifestyle (sleep, exercise, nutrition) optimized

GH-axis intervention is NOT reasonable when:

• Severe GH deficiency from pituitary pathology — needs rhGH replacement, not peptide-class intervention (the pituitary can't respond to GHRH analogs)
• Active malignancy — IGF-1 elevation is theoretically pro-tumorigenic; oncology guidance required
• Untreated diabetic retinopathy — GH/IGF-1 can worsen proliferative retinopathy
• Severe glucose intolerance — GH is counter-regulatory and can worsen glucose control
• Children or adolescents — needs pediatric endocrinology evaluation; no off-label peptide protocols appropriate
• Pregnancy/nursing — contraindicated

Baseline labs to order

Evidence tier: 3 — standard endocrine assessment.

Before any GH-axis intervention, baseline labs:

Primary GH-axis assessment: - IGF-1 (fasting; result interpreted against age-stratified reference range) - IGFBP-3 (less commonly used standalone but informative for IGF bioavailability assessment) - GH stimulation testing — if pituitary insufficiency is suspected (clonidine, arginine, or glucagon stimulation; insulin-tolerance is the gold standard but rarely done outside specialty settings)

Related hormones (because they influence interpretation and treatment decisions): - Total + free testosterone (men): low T amplifies GH-axis effects - DHEA-S - Estradiol + FSH/LH (women): post-menopausal status matters - TSH + free T4 (hypothyroidism suppresses GH-axis) - Cortisol AM (HPA axis assessment) - Vitamin D (25-OH)

Safety + monitoring labs: - Fasting glucose + HbA1c (baseline + at 8-12 weeks on therapy) - Lipid panel (baseline + periodically) - Comprehensive metabolic panel (baseline) - CBC (baseline)

Cancer screening status: - Age-appropriate cancer screening should be current before starting therapy - Specifically: colonoscopy, mammography (women), PSA discussion (men), skin exam

The IGF-1 result is the dominant decision driver. Use age-stratified reference ranges — adult-wide ranges aren't useful because the upper limit of normal at age 60 is much lower than at age 30. Most labs report age-stratified ranges; ensure your lab does.

What IGF-1 target makes sense

Evidence tier: 3 — clinician guidance + endocrinology consensus.

The target for GH-axis intervention is mid-normal IGF-1 for chronological age.

This is the most important framing in the entire field:

• Below mid-normal: probably under-replaced; reasonable to increase intervention
• Mid-normal: appropriately replaced; maintain protocol
• Upper-normal for age: at the ceiling of physiologic replacement; risk/benefit shifts unfavorably above here
• Supraphysiologic (above upper-normal-for-age): theoretically pro-tumorigenic and metabolically counterproductive; not a reasonable target for age-related decline

The clinic-driven push toward "youthful" IGF-1 (i.e., age-30 IGF-1 levels in a 60-year-old) is not appropriate for off-label age-related-decline therapy. The Laron syndrome research and the IGF-1-cancer epidemiology suggest that maintaining IGF-1 within physiologic-for-age range produces optimal longevity outcomes.

For sleep-focused intervention: targeting low-mid normal for age is reasonable. For body-comp focus: mid normal for age. For active aging support: low-mid to mid normal for age. Do not push toward upper-normal or beyond without specific oncology + endocrinology guidance.

Decision tree: sermorelin vs CJC+Ipa vs tesamorelin vs rhGH

Evidence tier: 3 — clinical framework.

Sermorelin alone is the right choice when: - Sleep is the primary goal - Mild age-related decline (IGF-1 low-normal-for-age) - Daily bedtime dosing is acceptable - Cost-effectiveness matters - WADA-tested status doesn't apply (sermorelin is prohibited)

CJC-1295 (without DAC) + Ipamorelin is the right choice when: - Sleep + body comp + recovery are all goals - Moderate age-related decline - Daily bedtime dosing is acceptable - Slightly higher cost than sermorelin alone is acceptable - See CJC-1295 + Ipamorelin stack guide

CJC-1295 (with DAC) + Ipamorelin is the right choice when: - Body composition is the primary goal - Sleep is not a primary concern (DAC produces sustained elevation rather than bedtime pulse) - Weekly dosing is preferred over daily - Higher monthly cost is acceptable

Tesamorelin (Egrifta) is the right choice when: - Visceral fat is the primary concern, especially with metabolic syndrome - HIV-associated lipodystrophy (FDA-approved indication) - Cost ($1,500-4,000/month) is acceptable - Long-term sustained protocol

Recombinant human GH (rhGH) is the right choice when: - Documented adult GH deficiency from pituitary pathology (Sheehan syndrome, pituitary tumor, post-radiation, traumatic brain injury, congenital) - Failed GH stimulation testing (e.g., peak GH <3 ng/mL on glucagon stimulation) - AGHD diagnosis established by endocrinologist - Insurance approval secured (rhGH is FDA-approved for AGHD) - Specialty endocrinology follow-up established

Lifestyle alone, no peptide intervention is the right choice when: - IGF-1 is mid-normal-for-age with adequate sleep + body comp + recovery - Lifestyle drivers (sleep, exercise, nutrition) aren't yet optimized - Cost or risk tolerance favors conservative approach - Active malignancy or other absolute contraindications

This decision-tree framing — sermorelin/CJC-no-DAC for sleep-primary, CJC-DAC for body-comp-primary, tesamorelin for visceral-fat-specific, rhGH for true deficiency — is the standard practitioner framework in 2026.

A reasonable protocol for age-related decline (sleep + body-comp goals)

Evidence tier: 4 — clinician practice; not RCT-anchored for the specific combination.

For a 50-year-old with IGF-1 in low-normal-for-age range, plausibly attributable symptoms, and primary goals of sleep + body comp:

Phase 1 (weeks 1-4): - Sermorelin 200 µg SC at bedtime, 5 nights/week - OR CJC-1295 (no DAC) 100 µg + ipamorelin 200 µg SC at bedtime, 5 nights/week - Single nightly dose, 30-60 min before sleep onset - Continue baseline lifestyle interventions - Recheck IGF-1 at week 8

Phase 2 (weeks 5-12): - Adjust dose based on week-8 IGF-1: increase 25-50% if still below mid-normal, maintain if mid-normal, reduce if approaching upper-normal - Continue cycling (5 nights on / 2 nights off) - Track subjective sleep quality + body comp metrics

Phase 3 (weeks 13-24): - Maintain at minimum effective dose targeting mid-normal IGF-1 - Insert 2-4 week breaks every 3-6 months to preserve pituitary responsiveness - Continue lab monitoring quarterly initially, then semi-annually - Reassess goals at 6 months: continue, taper, or cease

Avoid: - Targeting IGF-1 above upper-normal-for-age - Daily continuous dosing without cycling - Skipping IGF-1 + glucose monitoring - Substituting peptide for lifestyle (the peptide amplifies lifestyle, doesn't substitute)

When intervention isn't producing expected results

Evidence tier: 4 — clinical reasoning.

If 12 weeks of appropriately dosed protocol produces:

• No IGF-1 change: possible somatotroph hyporesponsiveness (rare); check pituitary function via stimulation testing; consider whether AGHD diagnosis is appropriate
• IGF-1 elevation without subjective benefit: the GH-axis decline may not be the actual driver of symptoms; reassess other contributors (sleep architecture issues, thyroid, gonadal hormone status, depression, chronic inflammation)
• Subjective benefit without IGF-1 change: protocol may be working via non-IGF-1 mechanisms; continue if benefit is sustained and IGF-1 doesn't escalate
• IGF-1 escalating above upper-normal-for-age: reduce dose; consider longer cycle-off periods

Don't keep escalating dose to chase an IGF-1 number. The mid-normal-for-age target is the right ceiling.

Side effects + monitoring

Evidence tier: 3 — well-characterized.

At physiologic dosing (mid-normal IGF-1 targets): - Mild water retention (typically first 2-4 weeks; usually resolves) - Occasional joint discomfort or "tightness" - Carpal-tunnel-like paresthesias (early sign of over-dosing) - Mild glucose-tolerance shift (monitor HbA1c)

At supraphysiologic dosing (above upper-normal IGF-1): - Persistent water retention / edema - Worsening glucose tolerance / pre-diabetes / diabetes - Significant joint discomfort - Carpal tunnel syndrome - Theoretical pro-tumorigenic effects (long-term)

Monitoring schedule: - IGF-1, fasting glucose, HbA1c at baseline, week 8-12, then semi-annually - Lipid panel at baseline + annually - Age-appropriate cancer screening continues per standard guidelines (not modified by GH-axis intervention) - Discontinue if active malignancy is diagnosed

WADA: GHRH analogs (sermorelin, CJC-1295, tesamorelin) and GH-releasing peptides (ipamorelin, GHRP-2, GHRP-6) are all on the WADA prohibited list (S2). Athletes subject to testing should avoid these protocols.

When rhGH is the right answer instead

Evidence tier: 3 — endocrinology consensus.

Recombinant human GH (rhGH; Somatropin) is FDA-approved for adult GH deficiency from documented pituitary pathology. Off-label use for age-related decline is not appropriate — rhGH bypasses the natural pulsatile GH release that maintains physiologic regulation.

rhGH is the right answer when: - Documented AGHD diagnosis (pituitary tumor, post-surgery, post-radiation, severe TBI, Sheehan's, congenital) - Failed GH stimulation testing (peak GH <3 ng/mL typically) - Endocrinology-managed therapy - Insurance approval and FDA-aligned indication

For age-related decline in someone with intact pituitary function and intact somatotroph responsiveness, peptide-class GHRH-analog therapy is appropriate; rhGH is not.

Limitations

This is not medical advice. Real limits:

• Get the baseline labs before any protocol; don't intervene blind
• Target mid-normal-for-age IGF-1, not supraphysiologic
• Lifestyle first: sleep, exercise, nutrition, alcohol moderation matter more than peptides for most users
• Don't substitute peptide for diagnosis: rule out sleep apnea, hypothyroidism, hypogonadism, depression before attributing symptoms to GH-axis decline
• Avoid in active malignancy — get oncology guidance
• WADA athletes: GH-axis peptides are prohibited; consider alternatives
• Don't use during pregnancy/nursing without specialist input
• Monitor labs at scheduled intervals — IGF-1 + fasting glucose + HbA1c
• Stop if persistent adverse effects emerge

The bottom line

Age-related GH decline is real, predictable, and partially reversible with peptide-class GHRH-analog therapy targeting mid-normal IGF-1 for chronological age. The intervention is reasonable for users in their 40s+ with documented IGF-1 in low-normal-for-age and plausibly attributable symptoms, after conventional drivers are addressed and lifestyle basics are optimized.

The right decision tree: sermorelin or CJC-1295-no-DAC for sleep-primary goals; CJC-1295-with-DAC for body-comp-primary; tesamorelin for visceral-fat-specific; rhGH for documented AGHD; lifestyle alone for mid-normal IGF-1 with adequate sleep and body composition.

The IGF-1 target matters more than any other single parameter: mid-normal for age, not supraphysiologic. The clinic-driven push toward "youthful" IGF-1 levels in older adults is not appropriate and shifts the risk/benefit calculation unfavorably. Conservative, physiologic-range intervention with proper monitoring is the right framework.

What we'll be tracking

• Long-term outcomes from physiologic-range GH-axis intervention vs supraphysiologic protocols
• IGF-1-cancer epidemiology updates
• PCAC July 23, 2026 review outcomes for sermorelin + CJC-1295 + ipamorelin + tesamorelin compoundability
• Updated age-stratified IGF-1 reference ranges from major reference labs

For ongoing context, see the Sleep & Growth Hormone pillar, the GH peptides for sleep architecture article, the CJC-1295 + Ipamorelin stack guide, the DSIP review, and the Tesamorelin (Egrifta) and off-label use.

References

• Bartke A. 2008. Growth hormone and aging: a challenging controversy. Clin Interv Aging. PMID 19021771
• Veldhuis JD, Roemmich JN, Richmond EJ, et al. 2005. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev. PMID 15901667
• Khorram O, Laughlin GA, Yen SS. 1997. Endocrine and metabolic effects of long-term administration of growth hormone-releasing hormone in older men and women. J Clin Endocrinol Metab. PMID 9141533
• Molitch ME, Clemmons DR, Malozowski S, et al. 2011. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. PMID 21632805
• Liu H, Bravata DM, Olkin I, et al. 2007. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. PMID 17227932